New cocktail of drugs and radiation targets Hard-to-Treat sarcoma
NCT ID NCT07205185
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This phase 2 trial tests a combination of the immunotherapy epalrotokewali, chemotherapy eribulin, targeted therapy anlotinib, and radiotherapy in 46 people with advanced soft tissue sarcoma that has progressed after prior treatment. The goal is to see if this mix can shrink tumors or slow the disease. Researchers will monitor safety and how well patients respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA (STS) are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Epalrotokewali (QL1706) plus eribulin, anlotinib, and radiotherapy
What this could lead to
If successful, this combination could offer a new treatment option for advanced soft tissue sarcoma that has stopped responding to standard therapies.
What could go wrong
This is an early phase 2 trial with only 46 participants, so results may not apply broadly. The combination also carries risks of serious side effects from the drugs and radiation.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.